213 related articles for article (PubMed ID: 38317241)
21. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
22. Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer.
Cohen H; Ben-Hamo R; Gidoni M; Yitzhaki I; Kozol R; Zilberberg A; Efroni S
Breast Cancer Res; 2014 Nov; 16(6):464. PubMed ID: 25410484
[TBL] [Abstract][Full Text] [Related]
23. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.
Peters AA; Buchanan G; Ricciardelli C; Bianco-Miotto T; Centenera MM; Harris JM; Jindal S; Segara D; Jia L; Moore NL; Henshall SM; Birrell SN; Coetzee GA; Sutherland RL; Butler LM; Tilley WD
Cancer Res; 2009 Aug; 69(15):6131-40. PubMed ID: 19638585
[TBL] [Abstract][Full Text] [Related]
24. Strong androgen receptor expression can aid in distinguishing GATA3+ metastases.
Boto A; Harigopal M
Hum Pathol; 2018 May; 75():63-70. PubMed ID: 29408697
[TBL] [Abstract][Full Text] [Related]
25. Androgen receptor signaling pathways as a target for breast cancer treatment.
Pietri E; Conteduca V; Andreis D; Massa I; Melegari E; Sarti S; Cecconetto L; Schirone A; Bravaccini S; Serra P; Fedeli A; Maltoni R; Amadori D; De Giorgi U; Rocca A
Endocr Relat Cancer; 2016 Oct; 23(10):R485-98. PubMed ID: 27528625
[TBL] [Abstract][Full Text] [Related]
26. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
[TBL] [Abstract][Full Text] [Related]
27. Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer.
Pizon M; Lux D; Pachmann U; Pachmann K; Schott D
J Transl Med; 2018 Dec; 16(1):356. PubMed ID: 30547831
[TBL] [Abstract][Full Text] [Related]
28. Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation.
Wang Y; Yu Q; He X; Romigh T; Altemus J; Eng C
Mol Cancer Ther; 2014 Feb; 13(2):517-27. PubMed ID: 24356815
[TBL] [Abstract][Full Text] [Related]
29. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
[TBL] [Abstract][Full Text] [Related]
30. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer.
Tozbikian GH; Zynger DL
Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800
[TBL] [Abstract][Full Text] [Related]
31. NR2F2 Orphan Nuclear Receptor is Involved in Estrogen Receptor Alpha-Mediated Transcriptional Regulation in Luminal A Breast Cancer Cells.
Erdős E; Bálint BL
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168782
[TBL] [Abstract][Full Text] [Related]
32. KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1.
Qiu MT; Fan Q; Zhu Z; Kwan SY; Chen L; Chen JH; Ying ZL; Zhou Y; Gu W; Wang LH; Cheng WW; Zeng J; Wan XP; Mok SC; Wong KK; Bao W
Oncotarget; 2015 Oct; 6(31):31702-20. PubMed ID: 26397136
[TBL] [Abstract][Full Text] [Related]
33. Targeting androgen receptor in estrogen receptor-negative breast cancer.
Ni M; Chen Y; Lim E; Wimberly H; Bailey ST; Imai Y; Rimm DL; Liu XS; Brown M
Cancer Cell; 2011 Jul; 20(1):119-31. PubMed ID: 21741601
[TBL] [Abstract][Full Text] [Related]
34. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
35. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
36. Ski-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription.
Abankwa D; Millard SM; Martel N; Choong CS; Yang M; Butler LM; Buchanan G; Tilley WD; Ueki N; Hayman MJ; Leong GM
BMC Biochem; 2013 Apr; 14():10. PubMed ID: 23566155
[TBL] [Abstract][Full Text] [Related]
37. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.
Xu G; Chhangawala S; Cocco E; Razavi P; Cai Y; Otto JE; Ferrando L; Selenica P; Ladewig E; Chan C; Da Cruz Paula A; Witkin M; Cheng Y; Park J; Serna-Tamayo C; Zhao H; Wu F; Sallaku M; Qu X; Zhao A; Collings CK; D'Avino AR; Jhaveri K; Koche R; Levine RL; Reis-Filho JS; Kadoch C; Scaltriti M; Leslie CS; Baselga J; Toska E
Nat Genet; 2020 Feb; 52(2):198-207. PubMed ID: 31932695
[TBL] [Abstract][Full Text] [Related]
38. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.
Hickey TE; Selth LA; Chia KM; Laven-Law G; Milioli HH; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell SN; Stelloo S; Iggo R; Alexandrou S; Caldon CE; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Lim E; Carroll JS; Tilley WD
Nat Med; 2021 Feb; 27(2):310-320. PubMed ID: 33462444
[TBL] [Abstract][Full Text] [Related]
39. Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms.
Feng J; Li L; Zhang N; Liu J; Zhang L; Gao H; Wang G; Li Y; Zhang Y; Li X; Liu D; Lu J; Huang B
Oncogene; 2017 May; 36(20):2775-2790. PubMed ID: 27893717
[TBL] [Abstract][Full Text] [Related]
40. Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation.
Duan L; Chen Z; Lu J; Liang Y; Wang M; Roggero CM; Zhang QJ; Gao J; Fang Y; Cao J; Lu J; Zhao H; Dang A; Pong RC; Hernandez E; Chang CM; Hoang DT; Ahn JM; Xiao G; Wang RT; Yu KJ; Kapur P; Rizo J; Hsieh JT; Luo J; Liu ZP
Nucleic Acids Res; 2019 Dec; 47(22):11623-11636. PubMed ID: 31647098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
